Float Short %

1.39

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

EPS Last/This Y

0.13

EPS This/Next Y

-0.06

Price

0.76

Target Price

Analyst Recom

Performance Q

-40.47

Relative Volume

0.53

Beta

1.5

Ticker: CUE

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-20	CUE	0.9403	0.11	0.00	766
2025-03-21	CUE	0.9846	0.11	0.00	776
2025-03-24	CUE	1.01	0.11	26.00	744
2025-03-25	CUE	0.982	0.13	0.00	756
2025-03-26	CUE	0.9801	0.13	0.00	756
2025-03-27	CUE	1	0.13	0.00	726
2025-03-28	CUE	0.9545	0.13	0.00	730
2025-03-31	CUE	0.8954	0.13	0.00	733
2025-04-01	CUE	0.7511	0.13	0.00	733
2025-04-02	CUE	0.7919	0.13	0.00	733
2025-04-03	CUE	0.7762	0.13	0.00	733
2025-04-04	CUE	0.6882	0.13	999.99	734
2025-04-07	CUE	0.6258	0.16	0.00	752
2025-04-08	CUE	0.6179	0.17	0.00	727
2025-04-09	CUE	0.6872	0.17	0.00	728
2025-04-10	CUE	0.7	0.17	0.00	728
2025-04-11	CUE	0.755	0.17	0.00	728
2025-04-14	CUE	0.818	0.17	0.00	728
2025-04-15	CUE	0.798	0.17	0.00	728
2025-04-16	CUE	0.7821	0.17	0.00	728
2025-04-17	CUE	0.7601	0.17	0.00	734
2025-04-18	CUE	0.762	0.17	0.00	734
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-20	CUE	0.96	50.0	-	-0.76
2025-03-21	CUE	0.98	50.0	-	-0.76
2025-03-24	CUE	1.03	50.0	-	-0.76
2025-03-25	CUE	1.00	50.0	-	-0.76
2025-03-26	CUE	0.99	50.0	-	-0.76
2025-03-27	CUE	1.01	50.0	-	-0.76
2025-03-28	CUE	0.92	50.0	-	-0.76
2025-03-31	CUE	0.91	50.0	-	-0.76
2025-04-01	CUE	0.75	50.0	-	-0.76
2025-04-02	CUE	0.79	50.0	-	-0.76
2025-04-03	CUE	0.75	50.0	-	-0.76
2025-04-04	CUE	0.68	50.0	-	-0.46
2025-04-07	CUE	0.64	50.0	-	-0.46
2025-04-08	CUE	0.62	50.0	-	-0.46
2025-04-09	CUE	0.70	50.0	-	-0.46
2025-04-10	CUE	0.71	50.0	-	-0.46
2025-04-11	CUE	0.78	50.0	-	-0.46
2025-04-14	CUE	0.79	50.0	-	-0.46
2025-04-15	CUE	0.80	50.0	-	-0.46
2025-04-16	CUE	0.77	50.0	-	-0.46
2025-04-17	CUE	0.76	50.0	-	-0.46
2025-04-18	CUE	0.76	50.0	-	-0.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-20	CUE	6.74	-14.33	1.52
2025-03-21	CUE	6.74	-14.33	1.52
2025-03-24	CUE	6.74	-14.33	1.52
2025-03-25	CUE	6.74	-14.33	1.52
2025-03-26	CUE	6.74	-14.33	1.37
2025-03-27	CUE	6.74	-14.33	1.37
2025-03-28	CUE	6.74	-14.33	1.37
2025-03-31	CUE	6.74	-14.33	1.37
2025-04-01	CUE	6.74	-14.33	1.37
2025-04-02	CUE	6.74	-14.33	1.37
2025-04-03	CUE	6.92	-14.33	1.40
2025-04-04	CUE	6.92	-14.33	1.40
2025-04-07	CUE	6.92	-14.64	1.40
2025-04-08	CUE	6.92	-14.64	1.40
2025-04-09	CUE	6.92	-14.64	1.40
2025-04-10	CUE	6.92	-14.64	1.39
2025-04-11	CUE	6.92	-14.64	1.39
2025-04-14	CUE	6.92	-14.34	1.39
2025-04-15	CUE	6.92	-14.34	1.39
2025-04-16	CUE	6.92	-14.34	1.39
2025-04-17	CUE	6.92	-14.34	1.39
2025-04-18	CUE	6.92	-14.34	1.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

6.92

Institutional Transactions

-14.34

Beta

1.5

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.6

Max Drawdown 5-Year %

-98.5

Target Price

P/E

Forward P/E

PEG

P/S

6.18

P/B

2.69

P/Free Cash Flow

EPS

-0.75

Average EPS Est. Cur. Y

-0.59

EPS Next Y. (Est.)

-0.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-437.97

Relative Volume

0.53

Return on Equity vs Sector %

-252.4

Return on Equity vs Industry %

-239

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

Cue Biopharma, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 41

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

stock quote shares CUE – Cue Biopharma Inc Stock Price stock today

news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch CUE – Cue Biopharma Inc yahoo finance google finance

stock history CUE – Cue Biopharma Inc invest stock market

stock prices CUE premarket after hours

ticker CUE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CUE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y